Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023
27 Settembre 2023 - 2:00PM
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume
measurement technology, today announces it will be attending the
Annual Scientific Meeting of the Heart Failure Society of America
(HFSA) which brings together the world’s leading experts in heart
failure at the Huntington Convention Center in Cleveland, Ohio from
October 6-9, 2023.
Meeting highlights include:
- New data showing
the benefits of blood volume measurement in the ambulatory
setting
- General session on the value of
blood volume measurement in managing congestion
- Heart Failure Advisory Board hosted
by Daxor
- Daxor to attend Corporate Member
Meeting with HFSA leadership
- Daxor to
present products and services in main Exhibit Hall
New data highlighting the applicability of blood
volume analysis (BVA) titled The Value of Blood Volume Analysis to
Guide Ambulatory Advanced Heart Failure Care (Poster #339, Monitor
23) will be highlighted in the e-Poster Hub accompanied by a
narrative from the principal investigator, Marc A. Silver, MD,
FACP, FACC, FCCP, FAHA, FHFSA.
“The HFSA’s Annual Scientific Meeting gathers
the best scientific minds focused on the latest heart failure
science, research and patient management,” said Michael Feldschuh,
CEO and President of Daxor Corporation. “We are thrilled that our
technology will be featured for a second year during a scientific
session panel discussion with leading experts titled Managing
Congestion: Targeting Pressure vs. Volume. BVA guided treatment in
heart failure has shown to reduce heart failure 30-day readmissions
by 56%, 30-day mortality by 82%, 1-year mortality by 86% and
results in a 57% reduction in length of stay when done on admission
(P<0.001). We look forward to sharing with the experts how our
diagnostic provides them with accurate, actionable data to
individualize treatment plans in both the inpatient and outpatient
settings - improving outcomes and reducing the total cost of
care.”
The company will be exhibiting at Booth 426.
Register for the event HFSA2023.
About Daxor
Corporation
Daxor Corporation (NASDAQ: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Grafico Azioni Daxor (NASDAQ:DXR)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Daxor (NASDAQ:DXR)
Storico
Da Mag 2023 a Mag 2024